Nalaganje...

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma

PURPOSE: The low-income subsidy (LIS) substantially lowers out-of-pocket costs for qualifying Medicare Part D beneficiaries who receive orally administered chemotherapy. We examined the association of LIS with the use of novel oral immunomodulatory drugs (IMiDs; lenalidomide and thalidomide) among b...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Olszewski, Adam J., Dusetzina, Stacie B., Eaton, Charles B., Davidoff, Amy J., Trivedi, Amal N.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2017
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652870/
https://ncbi.nlm.nih.gov/pubmed/28541791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.2447
Oznake: Označite
Brez oznak, prvi označite!